Genentech’s Actemra Receives Breakthrough For Systemic Sclerosis; Potential Future Beneficiary of OPEN ACT?
This article was originally published in RPM Report
Executive Summary
The potential new indication for Actemra could be an early beneficiary of a six-month patent extension, if the Cures legislation is enacted and orphan designation exclusivity remains a feature of the bill.
You may also be interested in...
Rare Disease OPEN-ing In PDUFA Possible For Drug Repurposing Advocates
OPEN ACT would provide additional six months of exclusivity when existing drugs are approved for rare diseases; congressional debate over the measure could get bogged down in drug pricing issues.
Autism Feedback To FDA: Focus On Communication, Redefine 'Irritability'
US FDA’s 22nd Patient-Focused Drug Development meeting focused on the challenging disease of autism. It also showed how far FDA has come in embracing the patient-input process over the past five years.
SMA Patient Meeting Showcases FDA Flexibility – And Appreciation From Advocates
US agency's top neurology review officials received warm reception during Patient Focused Drug Development meeting for Spinal Muscular Atrophy. They also delivered a strong message of continued engagement beyond the first drug approval.